Alvotech Ordinary Shares

ALVO

NASDAQ. Currency in USD

6.76 -0.23 ( -3.29% )

Real time prices: September 30

Market Cap.
1.68B
Beta (5Y monthly)
-
Price/Earnings
1,041.79
EPS (TTM)
0.01
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
68,708
1y Target Est.
13.60
Day's Range
6.12
-
7.40
52 Week's Range
5.20
-
14.04

Historical Summary

Performance
EPS growth
Share Buybacks

About Alvotech Ordinary Shares

Sector
Unknown
Industry
Unknown
Website
https://www.alvotech.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
0
Employees
784
Address
Saemundargata 15-19, Reykjavik, Iceland, 102
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Latest news

Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on...
By Benzinga - 1 week ago

Domino's Pizza, Athersys And Some Other Big Stocks Moving Higher On Friday
Domino's Pizza, Athersys And Some Other Big Stocks Moving Higher On Friday

U.S. stocks traded lower, with the Dow Jones dropping around 400 points on Friday. Here...
By Benzinga - 1 week ago

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®
Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

REYKJAVIK ICELAND; BAD VILBEL, GERMANY (September 22, 2022) — Alvotech (NASDAQ: ALVO), a global biotech...
By GlobeNewswire Inc. - 1 week ago

Alvotech og STADA hefja sölu á Hukyndra í Sviss og  auka aðgengi sjúklinga að adalimumab
Alvotech og STADA hefja sölu á Hukyndra í Sviss og auka aðgengi sjúklinga að adalimumab

Alvotech (NASDAQ First North: ALVO) og STADA Arzneimittel AG (STADA) tilkynntu í dag að sala...
By GlobeNewswire Inc. - 1 week ago

4 Analysts Have This to Say About Alvotech
4 Analysts Have This to Say About Alvotech

Alvotech (NASDAQ:ALVO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish...
By Benzinga - 3 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

Upgrades Macquarie upgraded the previous rating for Netflix Inc (NASDAQ:NFLX) from Underperform to Neutral. Netflix...
By Benzinga - 3 weeks ago

Alvotech birtir nýjar upplýsingar um stöðu  upprunalegu leyfisumsóknarinnar fyrir AVT02 í Bandaríkjunum
Alvotech birtir nýjar upplýsingar um stöðu upprunalegu leyfisumsóknarinnar fyrir AVT02 í Bandaríkjunum

Alvotech (NASDAQ First North: ALVO) tilkynnti í dag um samskipti við Matvæla- og lyfjaeftirlit Bandaríkjanna...
By GlobeNewswire Inc. - 3 weeks ago

Alvotech Reports Update on  Initial AVT02 Biologics License Application
Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
By GlobeNewswire Inc. - 3 weeks ago